Corlieve Therapeutics operates as a biotechnology company centered on creating therapeutic solutions for severe neurological disorders
Corlieve Therapeutics operates as a biotechnology company centered on creating therapeutic solutions for severe neurological disorders. The firm was established in the fourth quarter of 2019 by Richard Porter, Christophe Mulle, and Valerie Crepel. The company's foundation was a collaborative effort involving Kurma Partners, REGENXBIO Inc., SATT Aquitaine Science Transfert, and Inserm Transfert.